Z

Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456

Watchlist Manager
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Watchlist
Price: 13.75 CNY -1.22% Market Closed
Market Cap: 12.3B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Zhejiang Jiuzhou Pharmaceutical Co Ltd stock under the Base Case scenario is 20.76 CNY. Compared to the current market price of 13.75 CNY, Zhejiang Jiuzhou Pharmaceutical Co Ltd is Undervalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
20.76 CNY
Undervaluation 34%
Relative Value
Price
Z
Worst Case
Base Case
Best Case

Valuation Multiples

2.4
P/S
P/S
Price to Sales
2.4
vs History
90
vs Industry
44
Median 3Y
4.3
Median 5Y
6.5
Industry
2.4
Forward
2.1
More Details
19.7
P/E
P/E
Price to Earnings
19.7
vs History
80
vs Industry
27
Median 3Y
22.3
Median 5Y
38.2
Industry
20.3
Forward
13.2
More Details
8.7
P/OCF
P/OCF
Price to OCF
8.7
vs History
96
vs Industry
30
Median 3Y
18.8
Median 5Y
28.7
Industry
15.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
24
Median 3Y
37.1
Median 5Y
30.1
Industry
23.1
More Details
1.4
P/B
P/B
Price to Book Value
1.4
vs History
90
vs Industry
49
Median 3Y
3
Median 5Y
6.3
Industry
2
More Details
2
EV/S
EV/S
Enterprise Value to Sales
2
vs History
90
vs Industry
48
Median 3Y
3.4
Median 5Y
6.5
Industry
2.5
Forward
1.8
More Details
5.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.8
vs History
93
vs Industry
32
Median 3Y
9.1
Median 5Y
19.2
Industry
4.8
More Details
14.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
14.3
vs History
77
vs Industry
27
Median 3Y
15.9
Median 5Y
33.2
Industry
12.5
Forward
6
More Details
14.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
14.3
vs History
77
vs Industry
31
Median 3Y
15.9
Median 5Y
33.2
Industry
15.7
Forward
10
More Details
7.2
EV/OCF
EV/OCF
Enterprise Value to OCF
7.2
vs History
96
vs Industry
34
Median 3Y
15.9
Median 5Y
28.6
Industry
14.1
More Details
17.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
17.4
vs History
73
vs Industry
17
Median 3Y
42
Median 5Y
61
Industry
17.6
More Details
1.4
EV/IC
EV/IC
Enterprise Value to IC
1.4
vs History
88
vs Industry
45
Median 3Y
3.3
Median 5Y
5.6
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Zhejiang Jiuzhou Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
12.2B CNY 2.4 19.7 14.3 14.3
US
Eli Lilly and Co
NYSE:LLY
734.6B USD 15 66.1 35.5 38.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371.6B USD 4.2 17 12.5 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 7 20.2 13.3 15.1
CH
Roche Holding AG
SIX:ROG
212.3B CHF 3.5 25.6 9.6 11.3
UK
AstraZeneca PLC
LSE:AZN
163B GBP 4 28 130.7 197.1
CH
Novartis AG
SIX:NOVN
180B CHF 4.1 17 10 13.4
US
Merck & Co Inc
NYSE:MRK
199.8B USD 3.1 11.5 8.2 9.9
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.9B EUR 1.3 9.2 5 5.9
P/E Multiple
Earnings Growth PEG
CN
Z
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Average P/E: 23.8
19.7
18%
1.1
US
Eli Lilly and Co
NYSE:LLY
66.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.6
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
28
36%
0.8
CH
Novartis AG
SIX:NOVN
17
17%
1
US
Merck & Co Inc
NYSE:MRK
11.5
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.2
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Z
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Average EV/EBITDA: 395.2
14.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.5
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
14%
1
CH
Roche Holding AG
SIX:ROG
9.6
6%
1.6
UK
AstraZeneca PLC
LSE:AZN
130.7
9%
14.5
CH
Novartis AG
SIX:NOVN
10
5%
2
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Z
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Average EV/EBIT: 1 698.2
14.3
18%
0.8
US
Eli Lilly and Co
NYSE:LLY
38.8
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.3
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
197.1
21%
9.4
CH
Novartis AG
SIX:NOVN
13.4
10%
1.3
US
Merck & Co Inc
NYSE:MRK
9.9
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.